Other analysts also recently issued research reports about the company. Piper Sandler restated a “buy” rating and set a $26.50 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, February 4th. Cowen restated a “buy” rating and set a $32.00 price objective on shares of Milestone Pharmaceuticals in a report on Thursday, November 14th. Finally, Zacks Investment Research upgraded Milestone Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. Milestone Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $29.50.
NASDAQ MIST opened at $20.98 on Friday. The stock’s 50-day moving average price is $19.22 and its two-hundred day moving average price is $18.80. Milestone Pharmaceuticals has a 1 year low of $12.36 and a 1 year high of $27.95.
Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.04). On average, sell-side analysts expect that Milestone Pharmaceuticals will post -3.27 earnings per share for the current year.
In other news, major shareholder Holdings A/S Novo sold 240,000 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $16.00, for a total value of $3,840,000.00. Following the transaction, the insider now owns 2,434,470 shares in the company, valued at approximately $38,951,520. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Rtw Investments, Lp acquired 22,771 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was purchased at an average price of $15.85 per share, for a total transaction of $360,920.35. Insiders bought a total of 692,771 shares of company stock worth $11,323,920 in the last quarter.
An institutional investor recently raised its position in Milestone Pharmaceuticals stock. Millennium Management LLC increased its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 76.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,704 shares of the company’s stock after buying an additional 10,255 shares during the period. Millennium Management LLC owned 0.10% of Milestone Pharmaceuticals worth $410,000 at the end of the most recent reporting period. 53.37% of the stock is owned by institutional investors and hedge funds.
Milestone Pharmaceuticals Company Profile
Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.